Navigation Links
Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains
Date:8/27/2009

SARASOTA, Fla., Aug. 27 /PRNewswire/ -- Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies.

Lakewood-Amedex's nRNA product works by selectively silencing targeted genes in the viral genome. The company is building on the previously successful animal model study where mice infected with H1N1 type A influenza virus were given two doses of the L-A nRNA product and all survived while control and placebo dosed mice all died within six days. In addition L-A previously published a study demonstrating the effectiveness of its technology against the lethal H5N1 "bird flu" influenza virus in which a single intra-nasal dose of the company's nRNA product protected 100% of the infected chickens while placebo treated chickens all died within seven days.

Steve Parkinson, L-A's President and Chief Executive Officer, commented, "We had intended to develop our broadly applicable influ-RNA product to treat seasonal flu and as an emergency stockpile product in the event of a further outbreak of avian influenza, but due to the escalating global H1N1 pandemic and now the report of this virus having been isolated from turkeys in Chile, we feel it is critical to have a product that can target multiple strains of influenza and is useable year after year."

Mr. Parkinson explained that the L-A product does not work like a vaccine that stimulates the human host immune system to produce antibodies targeted at the specific viral strain composing the vaccine. Instead the nRNA product contains several short oligonucleotide sequences that are mirror images to unique sites on the viral mRNA from the viral replicative genes. When the nRNA comes into contact with its specific target, it hybridizes with the viral mRNA locking this mRNA up and preventing production of vital viral replicative proteins. Deprived of these, the virus is unable to multiply itself and rendered unable to spread and infect other cells.

Paul DiTullio, chief scientist for Lakewood-Amedex said, "We are essentially shutting the virus down in the infected person. By targeting the highly conserved replicative genes we have a product that should be useable for years even if the virus mutates. We are also hitting several genetic sites and the chances of them all mutating in the same season is minimal. Even if the H1N1 strain does undergo recombination with the deadly H5N1 strain our product will still shut it down." DiTullio added, "That is the limitation with vaccines. They stimulate antibody production in the host against the surface antigens of the virus but unfortunately it is the surface antigens that mutate most of the time requiring a new vaccine to be developed. Our product works independently of surface antigen mutation."

Mr. Parkinson commented, "The Company intends to complete its pre-clinical data package and enter human clinical trials as quickly as possible. We are talking to government agencies and potential partners and hope soon to have a universal anti-influenza product as an alternative to seasonal vaccines."

About Lakewood-Amedex Inc.

Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications covering its proprietary NuBiotics family of anti-microbial products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and others, and patents covering certain proprietary products targeting pandemic viral infections including Epstein Barr Virus (EBV), human and avian influenza, Hepatitis B and C and other clinical indications. The Company anticipates initiating human clinical trials for topical use of its Nu-3 NuBiotics compound in the near future for indications including diabetic ulcers and other topical infections. Future studies will involve the use of Nu-2 to treat broad spectrum antibiotic-resistant bacterial pulmonary and systemic infections. The company is currently conducting a human IRB clinical study to improve treatment of nasopharyngeal carcinoma in Changsha, China. Lakewood-Amedex is headquartered in Sarasota, FL.


'/>"/>
SOURCE Lakewood-Amedex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
2. New Consortium to Develop Drugs for Neglected Tropical Diseases
3. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
4. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
5. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
6. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
7. Cryo-Cell Announces Celle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.
8. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
9. Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value
10. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
11. ADHD Genes Found; Known to Play Roles in Neurodevelopment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017  BioSpecifics Technologies Corp. (NASDAQ: ... originated and continues to develop collagenase based-therapies ... collagenase clostridium histolyticum, or CCH, marketed as ... ®  in Europe, today announced that BioSpecifics, President, Tom ... the upcoming NobleCon13 - Noble Capital Markets, ...
(Date:1/24/2017)... MOINES, Iowa , Jan. 24, 2017 When tragedy ... who the victim is, what conditions they have, and who back ... was created—to keep loved ones informed about the safety of their ... information they need about victims in times of crisis. ... If you find yourself or ...
(Date:1/24/2017)... PORTLAND, Oregon and PUNE, India ... A new report published by Allied Market Research, titled, ... Vegetables, Bakery & Confectionary, Dairy & Frozen Dessert, Meat, ... Industries): Global Opportunity Analysis and Industry Forecasts, 2014-2022," projects ... to garner $426,275 million by 2022, growing at a ...
Breaking Medicine Technology:
(Date:1/24/2017)... York, New York (PRWEB) , ... January 24, 2017 , ... ... for Brazilian butt lifts is on the rise. According to the American Society ... augmentations since 2000. On average, these procedures are performed every 30 minutes of every ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... solution provider of enterprise software products, today announced a strategic partnership with ... Blue users to access and analyze their Fusion platform for building powerful enterprise ...
(Date:1/24/2017)... Calverton, MD (PRWEB) , ... January 24, 2017 , ... ... Year by MSC Cruises as part of the line’s 4th Annual MSC True ... Cruises’ top performing North American travel partners for the year based on overall business ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health Advocate Solutions, ... Series of webinars will start January 31 with a session about understanding healthcare ... health and benefits topics, including employee engagement, pricing transparency, population health and wellness, ...
(Date:1/24/2017)... ... January 24, 2017 , ... Center for Hispanic ... leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at City ... as its Hispanic Leader of the Month. City of Hope is committed to stay ...
Breaking Medicine News(10 mins):